A Powerful Molecular Synergy Between Mutant Nucleophosmin and Flt3-ITD Drives Acute Myeloid Leukemia in Mice

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2013 Mar 13

PMID 23478666

Citations 48

Authors

A Mupo

L Celani

O Dovey

J L Cooper

C Grove

R Rad

P Sportoletti

B Falini

A Bradley

G S Vassiliou

Affiliations

Soon will be listed here.

Citing Articles

Functions of the native NPM1 protein and its leukemic mutant.

Falini B, Sorcini D, Perriello V, Sportoletti P Leukemia. 2024; 39(2):276-290.

PMID: 39690184 DOI: 10.1038/s41375-024-02476-4.

Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.

Lap C, Abrahim M, Nassereddine S Ann Hematol. 2023; 103(7):2215-2229.

PMID: 37975931 DOI: 10.1007/s00277-023-05545-3.

In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis.

Lara-Astiaso D, Goni-Salaverri A, Mendieta-Esteban J, Narayan N, Del Valle C, Gross T Nat Genet. 2023; 55(9):1542-1554.

PMID: 37580596 PMC: 10484791. DOI: 10.1038/s41588-023-01471-2.

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.

Mill C, Fiskus W, Das K, Davis J, Birdwell C, Kadia T Leukemia. 2023; 37(6):1336-1348.

PMID: 36977823 PMC: 10244173. DOI: 10.1038/s41375-023-01882-4.

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.

Straube J, Eifert T, Vu T, Janardhanan Y, Haldar R, von Eyss B Leukemia. 2023; 37(4):741-750.

PMID: 36739348 PMC: 10079527. DOI: 10.1038/s41375-023-01832-0.

References

Kemp R, Ireland H, Clayton E, Houghton C, Howard L, Winton D . Elimination of background recombination: somatic induction of Cre by combined transcriptional regulation and hormone binding affinity. Nucleic Acids Res. 2004; 32(11):e92. PMC: 443557. DOI: 10.1093/nar/gnh090. View

Welch J, Ley T, Link D, Miller C, Larson D, Koboldt D . The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150(2):264-78. PMC: 3407563. DOI: 10.1016/j.cell.2012.06.023. View

Palmqvist L, Argiropoulos B, Pineault N, Abramovich C, Sly L, Krystal G . The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia. Blood. 2006; 108(3):1030-6. DOI: 10.1182/blood-2005-12-007005. View

Patel J, Gonen M, Figueroa M, Fernandez H, Sun Z, Racevskis J . Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12):1079-89. PMC: 3545649. DOI: 10.1056/NEJMoa1112304. View

Falini B, Bolli N, Liso A, Martelli M, Mannucci R, Pileri S . Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009; 23(10):1731-43. DOI: 10.1038/leu.2009.124. View

Whitman S, Archer K, Feng L, Baldus C, Becknell B, Carlson B . Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001; 61(19):7233-9. View

Sasaki M, Knobbe C, Munger J, Lind E, Brenner D, Brustle A . IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012; 488(7413):656-9. PMC: 4005896. DOI: 10.1038/nature11323. View

Lee B, Tothova Z, Levine R, Anderson K, Buza-Vidas N, Cullen D . FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007; 12(4):367-80. PMC: 2104473. DOI: 10.1016/j.ccr.2007.08.031. View

Hingorani K, Szebeni A, Olson M . Mapping the functional domains of nucleolar protein B23. J Biol Chem. 2000; 275(32):24451-7. DOI: 10.1074/jbc.M003278200. View

10.

Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H . Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998; 12(9):1333-7. DOI: 10.1038/sj.leu.2401130. View

11.

Grimwade D, Hills R . Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009; :385-95. DOI: 10.1182/asheducation-2009.1.385. View

12.

Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T . Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002; 21(16):2555-63. DOI: 10.1038/sj.onc.1205332. View

13.

Greenblatt S, Li L, Slape C, Nguyen B, Novak R, Duffield A . Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood. 2012; 119(12):2883-94. PMC: 3327463. DOI: 10.1182/blood-2011-10-382283. View

14.

Vassiliou G, Cooper J, Rad R, Li J, Rice S, Uren A . Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet. 2011; 43(5):470-5. PMC: 3084174. DOI: 10.1038/ng.796. View

15.

Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L . Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-66. DOI: 10.1056/NEJMoa041974. View